Company Filing History:
1 out of 1 
1 out of 6 
1 out of 832,912 Years Active: 2022
Title: Haruki Okamura: Innovator in Cancer Therapeutics
Introduction
Haruki Okamura is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of cancer therapeutics, particularly through his innovative patent that combines interleukin-18 (IL-18) with targeted antibodies. His work aims to enhance the effectiveness of cancer treatments.
Latest Patents
Okamura holds a patent for a therapeutic agent for cancer, which comprises a combination of IL-18 and a molecule-targeting antibody. This cancer therapeutic agent includes active ingredients such as IL-18 and one or more antibodies selected from a group that includes anti-PD-L1, anti-PD-1, anti-PD-L2, anti-CTLA-4, anti-CD25, anti-CD33, and anti-CD52 antibodies. This innovative approach has the potential to improve cancer treatment outcomes.
Career Highlights
Throughout his career, Okamura has worked with various organizations, including the Medical Research and Development Corporation. His dedication to advancing cancer therapies has positioned him as a key figure in the medical research community.
Collaborations
Okamura has collaborated with notable colleagues such as Kyosuke Yamanishi and Wen Li. These partnerships have contributed to the development of his groundbreaking therapeutic agent.
Conclusion
Haruki Okamura's contributions to cancer therapeutics through his innovative patent demonstrate his commitment to improving patient outcomes. His work continues to inspire advancements in medical research and development.